whatshot

AXSM   $98.68  0.50% Market Closed After Close 98.68 0.0

Axsome Therapeutics Inc
show_chart Advanced Chart of AXSM
Last Events:

2023-08-09 Trend pattern changed from расходящийся клин с наклоном вверх to сужающийся канал.

2023-08-09 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-05 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-05 Signal in MACD changed from bullish weakening to bearish. Oscillator MACD is in the negative territory it's higher than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-05 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 16
Target Price Mean 128.13
Mean unverified/preliminary 128.13 / 128.13
Target Price Low / High 71.00 / 180.00
Median / STD DEV 125.00 / 26.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None ActivelyBuy None
rsi ActivelyBuy ActivelyBuy None
macd Sell None None
stoch Sell None None
ma20 ActivelyBuy ActivelyBuy None
ma50 None None None
ma100 Buy Buy None
Candlestick PatternNov. 13, 2024 Shooting Star - is a candlestick that has a small body, a long upper shadow and a little or no lower tail. Considered to be a bearish pattern in an uptrend.
ISIN US05464T1043
ceo Dr. Herriot Tabuteau M.D.
Website https://www.axsome.com
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.